Bromocriptine in peripartum cardiomyopathy: A meta‐analysis with trial sequential analysis [PDF]
ESC Heart FailureBromocriptine has been proposed as a disease‐modifying therapy for peripartum cardiomyopathy (PPCM). The long‐term outcomes of bromocriptine use remain uncertain.
Umar G. Adamu +3 more
doaj +3 more sources
Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine [PDF]
BMC Cardiovascular Disorders, 2021 Background Ergot-derived dopamine agonists are thought to induce fibrotic changes in cardiac valve leaflets. We sought to determine the incidence of heart valve disease in women treated with bromocriptine compared with age and sex matched controls from ...
Marianne F. Clausen +8 more
doaj +2 more sources
Atherosclerosis enhances the efficacy of liposome-encapsulated bromocriptine in reducing the incidence of prolactinemia in pituitary tumors [PDF]
Journal of NanobiotechnologyIntranasal drug delivery via nanocarriers has long been a research focus for enhancing drug concentration in the brain. However, the strategy of exploiting blood–brain barrier (BBB) alterations in atherosclerotic mouse models to enhance nanoparticle ...
Zhe Zhang +12 more
doaj +2 more sources
Bromocriptine improves glucose tolerance in obese mice via central dopamine D2 receptor-independent mechanism. [PDF]
PLoS ONEBromocriptine, generally regarded as a dopamine D2 receptor agonist, has been used to treat patients with type 2 diabetes in the USA; however, its mechanisms of action including the receptors that mediate its anti-diabetic effects remain unclear ...
Hiroshi Tsuneki +11 more
doaj +2 more sources
Bromocriptine and its Antipyretic Effect in Central Hyperthermia [PDF]
Galicia ClínicaCentral hyperthermia is marked by rapid onset of elevated temperatures, resistant to antibiotics and antipyretics. Diagnosis requires exclusion of infectious sources and identification of an underlying neurological condition.
Sérgio Costa Monteiro +3 more
doaj +2 more sources
Molecular Metabolism, 2021 Background and objectives: The therapeutic effects of the dopamine D2 receptor (D2R) agonist, bromocriptine, in type 2 diabetes (T2D) have been attributed to central nervous system actions.
G. Tavares +11 more
doaj +2 more sources
Dual pancreatic adrenergic and dopaminergic signaling as a therapeutic target of bromocriptine
iScience, 2022 Summary: Bromocriptine is approved as a diabetes therapy, yet its therapeutic mechanisms remain unclear. Though bromocriptine’s actions have been mainly attributed to the stimulation of brain dopamine D2 receptors (D2R), bromocriptine also targets the ...
Despoina Aslanoglou +14 more
doaj +1 more source
Study on Synergistic Effect of Bromocriptine and Sitagliptin in Streptozotocin-induced Diabetic Rats [PDF]
Journal of Clinical and Diagnostic Research, 2021 Introduction: Diabetes mellitus is a potentially morbid condition with high prevalence worldwide. Restoration of euglycemia in type 2 diabetes mellitus is difficult to achieve due to its multifactorial pathogenesis and frequently requires multiple ...
Govindaraj Nileshraj +3 more
doaj +1 more source
The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas
BMC Endocrine Disorders, 2021 Background Prolactinoma is a functional pituitary adenoma that secretes excessive prolactin. Dopamine agonists (DAs) such as bromocriptine (BRC) are the first-line treatment for prolactinomas, but the resistance rate is increasing year by year, creating ...
Shuman Wang +6 more
doaj +1 more source
Impact of Nano-Bromocriptine on Egg Production Performance and Prolactin Expression in Layers
Animals, 2021 The current study aimed to investigate the potential use of nano-bromocriptine in improving the laying performance of late laying hens by modulating the prolactin gene expression.
Ahmed Dawod +7 more
doaj +1 more source